These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 20705357)

  • 21. Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
    Li XY; Wu JZ; Cao HX; Ma R; Wu JQ; Zhong YJ; Feng JF
    Oncol Rep; 2013 May; 29(5):1975-82. PubMed ID: 23440266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor--tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation.
    Imai H; Shukuya T; Takahashi T; Fujiwara S; Mori K; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Kaira K; Murakami H; Harada H; Endo M; Nakajima T; Yamamoto N
    Anticancer Res; 2013 Aug; 33(8):3279-84. PubMed ID: 23898092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
    Eberhard DA; Johnson BE; Amler LC; Goddard AD; Heldens SL; Herbst RS; Ince WL; Jänne PA; Januario T; Johnson DH; Klein P; Miller VA; Ostland MA; Ramies DA; Sebisanovic D; Stinson JA; Zhang YR; Seshagiri S; Hillan KJ
    J Clin Oncol; 2005 Sep; 23(25):5900-9. PubMed ID: 16043828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective study of second-line chemotherapy for non-small cell lung cancer selected according to EGFR gene status.
    Oshita F; Miyagi Y; Honda T; Murakami S; Kondo T; Saito H; Noda K; Yokose T; Kameda Y; Sakuma Y; Obata M; Yamada K
    J Exp Ther Oncol; 2010; 8(4):313-9. PubMed ID: 21222363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation.
    Koo DH; Kim KP; Choi CM; Lee DH; Lee JC; Lee JS; Jang SJ; Kim SW
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):197-206. PubMed ID: 25422153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
    Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
    Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
    Garassino MC; Martelli O; Broggini M; Farina G; Veronese S; Rulli E; Bianchi F; Bettini A; Longo F; Moscetti L; Tomirotti M; Marabese M; Ganzinelli M; Lauricella C; Labianca R; Floriani I; Giaccone G; Torri V; Scanni A; Marsoni S;
    Lancet Oncol; 2013 Sep; 14(10):981-8. PubMed ID: 23883922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erlotinib in previously treated non-small-cell lung cancer.
    Shepherd FA; Rodrigues Pereira J; Ciuleanu T; Tan EH; Hirsh V; Thongprasert S; Campos D; Maoleekoonpiroj S; Smylie M; Martins R; van Kooten M; Dediu M; Findlay B; Tu D; Johnston D; Bezjak A; Clark G; Santabárbara P; Seymour L;
    N Engl J Med; 2005 Jul; 353(2):123-32. PubMed ID: 16014882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
    Tiseo M; Rossi G; Capelletti M; Sartori G; Spiritelli E; Marchioni A; Bozzetti C; De Palma G; Lagrasta C; Campanini N; Camisa R; Boni L; Franciosi V; Rindi G; Ardizzoni A
    Lung Cancer; 2010 Mar; 67(3):355-60. PubMed ID: 19473722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
    Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
    Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials.
    Petrelli F; Borgonovo K; Cabiddu M; Barni S
    Clin Lung Cancer; 2012 Mar; 13(2):107-14. PubMed ID: 22056888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance.
    Kuo CH; Lin SM; Lee KY; Chung FT; Hsieh MH; Fang YF; Yu CT; Kuo HP
    Clin Lung Cancer; 2010 Jan; 11(1):51-6. PubMed ID: 20085868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.
    Wu JY; Yu CJ; Yang CH; Wu SG; Chiu YH; Gow CH; Chang YC; Hsu YC; Wei PF; Shih JY; Yang PC
    Am J Respir Crit Care Med; 2008 Oct; 178(8):847-53. PubMed ID: 18583573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of EGFR tyrosine kinase inhibitors in non-small-cell lung cancer patients with/without EGFR-mutation: evidence based on recent phase III randomized trials.
    Zhang WQ; Li T; Li H
    Med Sci Monit; 2014 Dec; 20():2666-76. PubMed ID: 25503781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population.
    Sluga R; VAN DEN Borne BEEM; Roepman P; Peters BJM; Kastelijn EA; Schramel FMNH
    Anticancer Res; 2018 Jan; 38(1):393-400. PubMed ID: 29277800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC.
    Fiala O; Pesek M; Finek J; Benesova L; Bortlicek Z; Minarik M
    Neoplasma; 2013; 60(4):425-31. PubMed ID: 23581415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group.
    Umemura S; Tsubouchi K; Yoshioka H; Hotta K; Takigawa N; Fujiwara K; Horita N; Segawa Y; Hamada N; Takata I; Yamane H; Kamei H; Kiura K; Tanimoto M
    Lung Cancer; 2012 Jul; 77(1):134-9. PubMed ID: 22487432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Individualized treatment of NSCLC: from research to clinical practice.
    Wang Y; Liu ZD; Zhao LM; Du CX; Xi XM; Mi YL; Peng Y; Li WG; Cheng F; Zhang XR; Zheng YQ; Tang KK; Yang HY; Chu DT
    Neoplasma; 2013; 60(5):538-45. PubMed ID: 23790173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer.
    Arrieta O; Cardona AF; Corrales L; Campos-Parra AD; Sánchez-Reyes R; Amieva-Rivera E; Rodríguez J; Vargas C; Carranza H; Otero J; Karachaliou N; Astudillo H; Rosell R;
    Lung Cancer; 2015 Feb; 87(2):169-75. PubMed ID: 25558790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.
    Soria JC; Mok TS; Cappuzzo F; Jänne PA
    Cancer Treat Rev; 2012 Aug; 38(5):416-30. PubMed ID: 22119437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.